Background: Severe pneumonia caused by coronavirus disease 2019 (COVID-19) is
characterized by inflammatory lung injury, progressive parenchymal stiffening and …

Background We have investigated the use of nebulized surfactant as a potential therapeutic
option for the patients with coronavirus disease 2019 (COVID-19)-associated acute …

Background COVID-19 causes acute respiratory distress syndrome (ARDS) and depletes
the lungs of surfactant, leading to prolonged mechanical ventilation and death. The …

Several pre-clinical and clinical trials show that exogenous pulmonary surfactant has clinical
efficacy in inflammatory lung diseases, especially ARDS. By infecting type II alveolar cells …

Introduction The dramatic impact of COVID-19 on humans worldwide has initiated an
extraordinary search for effective treatment approaches. One of these is the administration of …

Pulmonary surfactant constitutes an important barrier that pathogens must cross to gain
access to the rest of the organism via the respiratory surface. The presence of pulmonary …

Patients with COVID-19 report severe respiratory symptoms consistent with ARDS. The
clinical presentation of ARDS in COVID-19 is often atypical, as patients with COVID-19 …

Surfactant replacement might help recovery of low-compliance lung in severe COVID-19
pneumonia - Stefano Busani, Lorenzo Dall’Ara, Roberto Tonelli, Enrico Clini, Elena Munari …

SARS-CoV-2 directly targets alveolar epithelial cells and can lead to surfactant deficiency.
Early reports suggested surfactant replacement may be effective in improving outcomes. The …

Objectives SARS-Cov-2 virus preferentially binds to the Angiotensin Converting Enzyme 2
(ACE2) on alveolar epithelial type II cells, initiating an inflammatory response and tissue …